Anders Holt, ESC 2022: Risk of heart failure due to NSAID usage in diabetes, a Danish cohort study
Type 2 diabetes has been linked with subclinical cardiomyopathy and kidney function decline, therefore short-term non-steroidal anti-inflammatory drug (NSAID) use could potentially lead to the development of heart failure (HF) due to aberrations in fluid balances. In this touchCARDIO interview, we speak with Dr Anders Holt (Herlev and Gentofte Hospital, Copenhagen University Hospital, Hellerup, Denmark) to discuss the purpose and outcomes of a cohort study to assess associations between short-term NSAID use and the risk of HF in Danish cohort of patients with type 2 diabetes.
The abstract entitled ‘Non-steroidal anti-inflammatory drugs linked with heart failure in patients with diabetes’ was presented at the European Society of Cardiology (ESC) Congress 2022, 26 – 29 August 2022.
- What were the aims, design and eligibility criteria of your cohort study? (0:34)
- What were the findings of the study both overall and among individual NSAIDs? (3:44)
- What patient factors were associated with increased risk of heart failure? (6:13)
- What are the implications of these findings for clinical practice? (10:09)
Disclosures: Anders Holt has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of ESC 2022
Access more content on Heart Failure here
Share this Video
Related Videos In Heart Failure
Gregg Stone, ACC 2023: COAPT trial results – Transcatheter edge-to-edge repair with MitraClip device for functional mitral regurgitation in heart failure
The COAPT trial investigated the use of the MitraClip a novel device for patients with secondary mitral regurgitation, a condition in which blood leaks backward through the mitral valve into the left atrium of the heart. In this touchCARDIO interview Dr Gregg Stone (Mount Sinai Heart Health System, New York City, NY, USA) discusses the […]
John Boehmer, ACC 2023: MicrocorTM device for heart failure management, the BMAD trial
The BMAD trial investigated patients with heart failure assessed the use of the Microcor device on readmission rates. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, USA) to discuss purpose, findings and clinical implications of the BMAD trial in […]
John Boehmer, ACC 2023: The MicrocorTM device, monitoring tool for heart failure
The most common cause of hospital admission due to heart failure is due to excess fluid retention. The MicrocorTM device monitors fluid levels in the lungs to aid in patient management. In this touchCARDIO interview, we speak with Dr John Boehmer (Penn State Milton S Hershey Medical Center, Penn State College of Medicine, Hershey, PA, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!